학술논문

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas
Document Type
Article
Source
In: Cancer. (Cancer, 15 February 2019, 125(4):586-600)
Subject
Language
English
ISSN
10970142
0008543X